Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIα expression

Biochemical Pharmacology

Volumn 61, Issue 7, 2001, Pages 795-802

  Salmena, Leonardo ^a   Lam, Viengthong ^a   Peter McPherson, J ^a   Goldenberg, Gerald J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cell cycle; Degradation; MG132; Proteasome; Topoisomerase II ; Ubiquitin

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CARBOBENZOXYLEUCYLLEUCYLNORVALINAL; CYSTEINE; DNA TOPOISOMERASE (ATP HYDROLYSING); LACTACYSTIN; METHIONINE; MG 115; PROTEASOME; PROTEASOME INHIBITOR; SULFUR 35; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME DEGRADATION; ENZYME REGULATION; ENZYME RELEASE; HALF LIFE TIME; HELA CELL; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ANTIGENS, NEOPLASM; CELL CYCLE; CELL EXTRACTS; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; HELA CELLS; HUMANS; ISOENZYMES; LEUPEPTINS; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR CELLS, CULTURED;

EID: 0035313393     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00580-9     Document Type: Article

References (26)

1. DNA topoisomerases
2. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism
3. DNA topoisomerases: Essential enzymes and lethal targets
4. Eukaryotic DNA topoisomerase IIβ
5. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells
6. Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase
7. Effects of topoisomerase I inhibition on the expression of topoisomerase IIα measured with fluorescence image cytometry
8. Temporal and spatial distribution of DNA topoisomerase II alters during proliferation, differentiation, and apoptosis in HL-60 cells
9. Analysis of M phase-specific phosphorylation of DNA topoisomerase II
10. Induction of ubiquitin conjugating enzyme activity for degradation of topoisomerase IIα during adenovirus E1A-induced apoptosis
11. Degradation of topoisomerase IIα during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system
12. The ubiquitin system
13. Identification of the nature of the modification that causes the shift of DNA topoisomerase IIβ to apparent higher molecular weight forms in the M phase
14. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
15. The measurement of ubiquitin and ubiquitinated proteins
16. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
17. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae
18. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells
19. Lactacystin, proteasome function, and cell fate
20. The mechanisms - Pathways of intracellular proteolysis
21. Cyclin is degraded by the ubiquitin pathway
22. Cell cycle-regulated expression, phosphorylation, and degradation of p55Cdc. A mammalian homolog of CDC20/Fizzy/slp1
23. Mitotic destruction of the cell cycle regulated NIMA protein kinase of Aspergillus nidulans is required for mitotic exit
24. Separation of sister chromatids in mitosis requires the Drosophila pimples product, a protein degraded after the metaphase/anaphase transition
25. Glucose-regulated stresses cause degradation of DNA topoisomerase IIα by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells
26. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs